Johns Hopkins researchers developed an ultra-sensitive blood test that can detect cancer up to 3 years before clinical symptoms appear. Among 52 participants, 8 of 26 later-diagnosed cases showed markers in archived blood samples. The test, using multicancer ultra-sensitive sequencing, suggests dramatic potential for early detection. It’s not yet FDA-approved, and experts stress the importance of further validation and clear clinical follow-ups. Still, it could revolutionize early treatment, especially for cancers with stark survival differences based on stage.
Source: NY Post nyulangone.org
0 Comments